Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 235

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial

Open access
Gridelli, Cesare, Ciardiello, Fortunato, Gallo, Ciro, Feld, Ronald, Butts, Charles, Gebbia, Vittorio, Maione, Paolo, Morgillo, Floriana, Genestreti, Giovenzio, Favaretto, Adolfo, Leighl, Natasha, Wierzbicki, Rafal, Cinieri, Saverio, Alam, Yasmin, Siena, Salvatore, Tortora, Giampaolo, Felletti, Raffaella, Riccardi, Ferdinando, Mancuso, Gianfranco, Rossi, Antonio, Cantile, Flavia, Tsao, Ming-Sound, Saieg, Mauro, da Cunha Santos, Gilda, Piccirillo, Maria Carmela, Di Maio, Massimo, Morabito, Alessandro, Perrone, Francesco · 2012 · Journal of Clinical Oncology

Abstract

Purpose: Erlotinib prolonged survival of unselected patients with advanced non–small-cell lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II studies suggested it might be an alternative to first-line chemotherapy. A randomized phase III trial was designed to test whether first-line erlotinib followed at progression by cisplatin-gemcitabine was not inferior in terms of survival to the standard inverse sequence. Patients and Methods: Patients with stage IIIB (with pleural effusion or supraclavicular nodes) to IV NSCLC and performance status of 0 to 1 were eligible. With a 95% CI upper limit of 1.25 for the hazard ratio (HR) for death, 80% power, a one-sided α = .025, and two interim analyses, a sample size of 900 patients was planned. Results: At the first planned interim analysis with half the events, the inferiority boundary was crossed, and the Independent Data Monitoring Committee recommended early termination of the study. Seven hundred sixty patients (median age, 62 years; range, 27 to 81 years) had been randomly assigned. Baseline characteristics were balanced between study arms. As of June 1, 2011, median follow-up was 24.3 months, and 536 deaths were recorded (263 in the standard treatment arm and 273 in the experimental arm). Median survival was 11.6 months (95% CI, 10.2 to 13.3 months) in the standard arm and 8.7 months (95% CI, 7.4 to 10.5 months) in the experimental arm. Adjusted HR of death in the experimental arm was 1.24 (95% CI, 1.04 to 1.47). There was no heterogeneity across sex, smoking habit, histotype, and epidermal growth factor receptor (EGFR) mutation. Conclusion: In unselected patients with advanced NSCLC, first-line erlotinib followed at progression by cisplatin-gemcitabine was significantly inferior in terms of overall survival compared with the standard sequence of first-line chemotherapy followed by erlotinib.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2011.41.2056

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 235

Metadata

Authors
Gridelli, C., Ciardiello, F., Gallo, C., Feld, R., Butts, C., Gebbia, V., Maione, P., Morgillo, F., Genestreti, G., Favaretto, A., Leighl, N., Wierzbicki, R., Cinieri, S., Alam, Y., Siena, S., Tortora, G., Felletti, R., Riccardi, F., Mancuso, G., Rossi, A., Cantile, F., Tsao, M.-S., Saieg, M., da Cunha Santos, G., Piccirillo, M. C., Di Maio, M., Morabito, A., & Perrone, F.
Venue
Journal of Clinical Oncology
Published
2012-08-20
Volume
30
Issue
24
Pages
3002-3011
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2128278369
Cited by
235
References
14
FWCI
31.30
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial. https://app.cochat.ai/papers/10.1200/jco.2011.41.2056
The paper
Gridelli, C., Ciardiello, F., Gallo, C., Feld, R., Butts, C., Gebbia, V., Maione, P., Morgillo, F., Genestreti, G., Favaretto, A., Leighl, N., Wierzbicki, R., Cinieri, S., Alam, Y., Siena, S., Tortora, G., Felletti, R., Riccardi, F., Mancuso, G., . . . Perrone, F. (2012). First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.41.2056

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.